Tumor necrosis factor receptor 1, TNF-R1, Tumor necrosis factor receptor type I, TNF-RI, TNFR-I, CD120a, TNF Receptor Superfamily Member 1A, TNFAR, Tumor Necrosis Factor Receptor Superfamily Member 1A, TNF-R-I, TNF-R55, TNFR60, TNF-R, TNFR1, Tumor Necrosis Factor Receptor Superfamily, Member 1A, Tumor Necrosis Factor Receptor 1A Isoform Beta, Tumor Necrosis Factor Binding Protein 1, Tumor Necrosis Factor Receptor Type 1, Tumor Necrosis Factor Receptor Type I, Tumor Necrosis Factor-Alpha Receptor, Tumor Necrosis Factor Receptor 1, CD120a Antigen, TNFRSF1A, TNFR55, P55-R, TBP1, FPF, TBPI, p55, p60


Tumor necrosis factor receptor superfamily member 1A is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFα).Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase.

KO Status

F2 (-/-)

Drug Information

Drug in clinical trials: 1
Latest Research Phase: Phase 2 Clinical

Drug Name





Clinical Trials

NKG2D CAR-T cell therapy (Uwell Biopharma)


Uwell Biopharma


IPH-2301, IPH-23XX, JNJ-4500, JNJ-64304500, NNC-0142-002, NNC-0142-0002, NNC-0142-0000-0002, NN-8555

Phase 2 Clinical


Alopecia Areata, Arthritis, Rheumatoid, Celiac Disease, Inflammation, Crohn Disease


GSK-2862277, 2862277

Phase 2 Clinical

Glaxosmithkline Plc

Respiration Disorders, Respiratory Distress Syndrome, Adult, Acute Lung Injury



Phase 1 Clinical

Eli Lilly And Company

Chronic Urticaria, Dermatitis, Atopic



Phase 1 Clinical

Heat Biologics


NKG2D CAR-T Cell therapy (Yake Biotechnology)

Phase 1 Clinical

Yake Biotechnology Ltd

Leukemia, Myeloid, Acute


MK-6105, ASLAN-004, CSL-334

Phase 1 Clinical

Csl Ltd, Merck Sharp & Dohme Corp

Dermatitis, Atopic, Hypersensitivity





The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Purification of two types of TNF inhibitors in the urine of the patient with chronic glomerulonephritis

Suzuki J., Tomizawa S., Arai H., Seki Y., Maruyama K., Kuroume T.,

Nephron 66:386-390(1994)

Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors

Engelmann H., Novick D., Wallach D.,

J. Biol. Chem. 265:1531-1536(1990)

Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis

Zhu N., Khoshnan A., Schneider R., Matsumoto M., Dennert G., Ware C.F., Lai M.M.C.,

J. Virol. 72:3691-3697(1998)

The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation

Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.,

EMBO J. 18:3044-3053(1999)

F1Aalpha, a death receptor-binding protein homologous to the Caenorhabditis elegans sex-determining protein, FEM-1, is a caspase substrate that mediates apoptosis

Chan S.-L., Tan K.-O., Zhang L., Yee K.S.Y., Ronca F., Chan M.-Y., Yu V.C.,

J. Biol. Chem. 274:32461-32468(1999)

Identification of Grb2 as a novel binding partner of tumor necrosis factor (TNF) receptor I

Hildt E., Oess S.,

J. Exp. Med. 189:1707-1714(1999)

Prevention of constitutive TNF receptor 1 signaling by silencer of death domains

Jiang Y., Woronicz J.D., Liu W., Goeddel D.V.,

Science 283:543-546(1999)

A death receptor-associated anti-apoptotic protein, BRE, inhibits mitochondrial apoptotic pathway

Li Q., Ching A.K.-K., Chan B.C.-L., Chow S.K.-Y., Lim P.-L., Ho T.C.-Y., Ip W.-K., Wong C.-K., Lam C.W.-K., Lee K.K.-H., Chan J.Y.-H., Chui Y.-L.,

J. Biol. Chem. 279:52106-52116(2004)

Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1

Gomez M.I., Lee A., Reddy B., Muir A., Soong G., Pitt A., Cheung A., Prince A.,

Nat. Med. 10:842-848(2004)